Big Pharma promised Trump new American jobs for tax cuts and deregulation. But the vow comes after a 5-year purge
Amgen CEO Bob Bradway has never been reluctant to bring out the ax and chop staff.
Late in 2014, the company announced their original restructuring plans to reduce payroll was too modest, upping its goal on job cuts to 4,000. And the pharma giant followed up in the spring of 2015 by axing about 300 staffers after Bradway decided to shutter the Onyx campus obtained with its acquisition of Kyprolis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.